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A B S T R A C T
Within clinical vaccinations, recombinant antigens are routinely entrapped inside or adsorbed onto the surface
of aluminium salts in order to increase their immunological potency in vivo. The efficacy of these immunisations
is highly dependent upon the recognition and uptake of these complexes by professional phagocytes and their
subsequent delivery to the draining lymph nodes for further immunological processing. While monocytes have
been shown to internalise aluminium adjuvants and their adsorbates, the role of macrophages in this respect has
not been fully established. Furthermore, this study explored the interaction of THP-1 macrophages with alu-
minium-based adjuvants (ABAs) and how this relationship influenced the survival of such cells in vitro. THP-1
macrophages were exposed to low concentrations of ABAs (1.7 μg/mL Al) for a maximum of seven days. ABA
uptake was determined using lumogallion staining and cell viability by both DAPI (4′,6-diamidino-2-pheny-
lindole) staining and LDH (lactate dehydrogenase) assay. Evidence of ABA particle loading was identified within
cells at early junctures following treatment and appeared to be quite prolific (> 90% cells positive for Al signal
after 24 h). Total sample viability (% LDH release) in treated samples was predominantly similar to untreated
cells and low levels of cellular death were consistently observed in populations positive for Al uptake. It can thus
be concluded that aluminium salts can persist for some time within the intracellular environment of these cells
without adversely affecting their viability. These results imply that macrophages may play a role in the systemic
translocation of ABAs once administered in the form of an inoculation.
1. Introduction
In order to increase both the longevity and potency of the im-
munological response incurred post immunisation, formulations con-
taining recombinant antigens are often supplemented with aluminium
salts. These immunopotentiating compounds are physicochemically
distinct and include aluminium oxyhydroxide (AH), aluminium hy-
droxyphosphate (AP) and the recently introduced proprietary suspen-
sion aluminium hydroxyphosphate sulphate (AAHS). Such materials
remain the archetypal choice of adjuvant included within clinically-
approved vaccinations and are considered highly efficacious with re-
gards to the generation of humoral/antibody mediated immunity (see
reviews [1,2]). However, their ability to induce Th1 responses appears
to be severely restricted [3–6] and as such precludes their inclusion
within inoculations designed to target pathogens where a cell-mediated
counterstrike is required. Concerns have also been expressed regarding
the safety of these adjuvants, most notably the emergence of macro-
phagic myofasciitis (MMF), a disease attributed to the chronic in-
tramuscular influx of periodic acid–Schiff-positive antigen-presenting
cells (APCs) in predisposed individuals following AH administration
[7–10].
The biological fate of aluminium-based adjuvant (ABA) particles
once introduced by means of vaccination into the interstitial milieu
continues to be the source of some debate. Current consensus suggests
that a proportion of the aluminium injected remains localised at the
injection site for extended periods of time. Indeed, the cumulative ab-
sorption of AH & AP into the bloodstream is substantially impeded due
to their diminutive dissolution rates under simulated in vivo conditions
[11,12] and equated to 17 & 51% respectively over a period of 28 days
[12,13]. Consistent with such observations, immunisation of primates
against diphtheria-tetanus induced the formation of localised alumi-
nium-rich granulomas/nodules, which could endure for up to
12months post inoculation [14]. Munks et al. concluded that similar
nodules formed following intraperitoneal injection consisted pre-
dominantly of fibrin and due to the concomitant presence of histones
bore a striking resemblance to extracellular traps (ETs); however, these
pathological hallmarks were deemed redundant with regards to the
adjuvanticity of aluminium salts [15]. Such phenomena were also
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observed subcutaneously at early junctures post vaccination, although
these were typically rich in neutrophilic activity and provided an
abundant source of extracellular DNA through NETosis associated me-
chanisms, which subsequently enhanced the production of ovalbumin-
specific IgG1 [16]. While the formation of an antigen depot is generally
considered dispensable in relation to the adjuvant activity of aluminium
salts [17], it is possible that these structures may contribute to the
modus operandi of these compounds through the generation of localised
damage-associated molecular patterns (DAMPs), whose release is
known to facilitate the recruitment of leukocytes towards sites of
physiological insult [18,19].
Furthermore, the development of robust adaptive immune re-
sponses post vaccination is highly dependent upon the successful
translocation of antigenic material, presumably as part of an antigen-
adjuvant complex, to the draining lymph nodes for immunological
processing [20]. While the large hydrodynamic size of ABAs in biolo-
gical fluid stymies the chances of independent migration [21], their
micron- sized dimensions expedite their recognition and uptake by
professional phagocytes [22], the presence of which is observed at the
site of injection as early as 2 h post inoculation [23]. Monocytes, in
particular, have a voracious appetite for aluminium salts [21,24,25]
which in turn provides a potent stimulus for their differentiation into a
mature dendritic phenotype [26–28]. These specialised APCs are re-
sponsible for much of the antigen-presentation and processing observed
following vaccine administration [29] and thus play a pivotal role in
the immunomodulatory events directed by ABAs [29–32].
A tentative role for macrophages in these proceedings has also been
postulated, despite their seemingly superfluous contribution to murine
T-cell priming and antibody generation following immunisation with
AH [33]. The direct interaction of AH with tissue-resident macrophages
promotes leukocyte chemotaxis [27] and induces alterations in surface
marker expression towards that typically associated with dendritic cells
[34,35]. While some reports suggest that AH microparticles are not
engulfed by macrophages in vitro [36,37], others have indicated that
monocyte-derived macrophages internalise ABAs present in both the
intramuscular [38] and subcutaneous cavities in vivo [39]. These cells
are then capable of disseminating their cargo throughout the body to
myriad locations including the spleen, lymphatic nodes and brain
[38–41]. The extent or likelihood of systemic translocation is expected
to be governed by the ability of loaded macrophages to survive for
extended periods of time post particulate uptake. Preliminary research
has indicated that ABAs can promote DNA synthesis in bone-marrow
derived macrophages (BDMCs) which enhances cellular endurance
[42]; however, this short-term study did not explicitly follow ABA up-
take/recognition in conjunction with viability. In order to determine
the survival prospects of APCs in the presence of ABAs, this study
monitored the direct interaction of THP-1 macrophages with low doses
of clinically relevant ABAs in tandem with their viability for one week
post initial exposure.
2. Materials and methods
2.1. Adjuvants
Aluminium oxyhydroxide (Alhydrogel® 2%) and aluminium hy-
droxyphosphate (Adju-Phos®) were obtained from Brenntag Biosector,
Denmark as aseptic colloidal suspensions containing a total aluminium
(Al) concentration of ca 10 and 5mg/mL respectively. Pyrogenicity
testing was performed by the manufacturer and endotoxin levels were
certified as within acceptable limits.
2.2. Cell culture protocols
2.2.1. Maintenance of THP-1 parent cultures
Growing cultures of THP-1 cells (ECACC 88081201), a line origin-
ally isolated from the blood of a paediatric patient suffering from acute
monocytic leukaemia [43], were obtained from Public health England
(PHE). Parent cultures were maintained in Corning® T25 flasks at a
density of 5×105–8× 105 cells/mL within GlutaMAX™ RPMI 1640
medium supplemented with an additional 20 μg/mL gentamycin and
10% foetal bovine serum (R10 medium). Flasks were housed under
humidified conditions at 37 °C, 5% CO2.
2.2.2. THP-1 differentiation and treatment
Prior to differentiation, the viability of cells isolated from parent
cultures was determined using a trypan blue exclusion test. Provided
that the viability of enumerated monocytes exceeded 90%, cells were
seeded into 24- or 96-well plates at a density of 2×105 and 2× 104
cells per well respectively and differentiated using 50 nM PMA (phorbol
12-myristate 13-acetate) for 48 h (37 °C, 5% CO2). Cells in 24-well
plates were differentiated onto 13mm round coverslips, which had
previously been sanitised using 70% v/v EtOH. Following differentia-
tion, the PMA-containing medium was removed and replaced with fresh
R10 medium in which cells were allowed to rest under the same en-
vironmental conditions for a further 24 or 48 h depending on the in-
tended purpose of proceeding experiments.
2.2.3. ABA treatment of THP-1 macrophages
ABA formulations containing ca 300 μg/mL Al were initially pre-
pared through the addition of adjuvant stock solutions to physiological
saline (0.9% NaCl, pH 7, 0.22 μm filtered). These solutions were further
diluted in R10 medium to a concentration of 1.7 μg/mL Al before re-
placing the resting medium originally residing in wells designated for
adjuvant treatment. Cells were treated on day 2 of the rest period fol-
lowing differentiation and incubated at 37 °C (5% CO2) for the duration
of the experimental procedure. Macrophages were analysed on days 1,
3 & 7 post adjuvant exposure, which corresponded to days 3, 5 & 9 post
PMA withdrawal. For preliminary uptake experiments using fixed cells,
samples were also analysed 3 h after treatment with ABAs.
2.3. Lumogallion staining (Al detection)
Macrophagic interaction with ABAs was monitored using lumo-
gallion staining, a highly sensitive ligand for aluminium [44] which
emits a fluorescence signal at ca 590 nm upon complexation with the
ionic form of the metal [45]. The following protocol was adapted from
that used by Mold et al. [25] for the purpose of labelling native THP-1
monocytes in vitro.
A stock solution of lumogallion (1mM, Sigma Aldrich, UK) was
prepared in ultrapure water (0.067 μS/cm) and filtered using a sterile
0.22 μm membrane in order to remove potential microbial or particu-
late contamination. Both adjuvant-treated and control wells were
spiked with 20 μL of the stock solution (final concentration - 100 μM per
well) 2 h prior to fixation or DAPI staining of live cells.
2.4. Dead cell labelling and detection (live cell staining)
Labelling of nuclear material through DAPI staining of live cell
populations was used in order to determine the relative number of
membrane-compromised macrophages per treatment.
DAPI (4′,6-diamidino-2-phenylindole, dihydrochloride) was pro-
cured from Thermo Fisher Scientific, UK and stock aliquots (5mg/mL)
were prepared through dissolution of the powder in ultrapure water
(0.22 μm filtered). Aliquots were serially diluted prior to experimental
use first in ultrapure water (1:100) and then in 1X Dulbecco's phos-
phate-buffered saline (DPBS) (+Ca2+ and Mg2+) (1:500) to achieve a
final working concentration of 0.1 μg/mL.
ABA-treated and control cells were washed once with warm 1X DPBS
(+Ca2+ and Mg2+) before the addition of 100 μL dilute DAPI stain to
wells and thereafter incubated at RT for 15min in the absence of light.
Post incubation, macrophages were washed once more to remove excess
DAPI stain and analysed immediately using fluorescence microscopy.
E. Shardlow, et al. Journal of Inorganic Biochemistry 203 (2020) 110915
2
2.5. Fixation procedure
Cells cultured in 24-well plates were washed once with warm 1X
DPBS (+Ca2+ and Mg2+) and fixed for 20min at RT using sterile fil-
tered paraformaldehyde (4% w/v in 0.9% NaCl+ 25mM PIPES (pi-
perazine-N,N′-bis(2-ethanesulfonic acid)), pH 7.4). Following a further
two washes with 1X DPBS (-Ca2+ and Mg2+), coverslips were mounted
onto slides using a small amount of DAPI containing ProLong® Gold
Antifade Reagent (Life technologies, UK) and were allowed to rest for
24 h at 4 °C prior to analysis by fluorescence microscopy.
2.6. Fluorescence microscopy (fixed cells)
The time-dependent interaction of ABA particles with THP-1 mac-
rophages over an initial period of 2 days was monitored using a BX50
fluorescence microscope (Olympus, UK) fitted with a BX-FLA reflected
fluorescent light attachment (mercury source) and a vertical illumi-
nator.
Lumogallion fluorescence emanating from Al positive material (or-
ange signal) was detected through the use of an Olympus U-MNIB3
fluorescence filter cube (λex: 470 –495 nm, dichromatic mirror: 505 nm,
longpass λem: 510 nm).
DAPI fluorescence originating from labelled cell nuclei (blue signal)
was observed using an Olympus U-MWU2 fluorescence filter cube (λex:
330–385 nm, dichromatic mirror: 400 nm, longpass λem: 420 nm).
Images were acquired using a ColorView III CCD camera using the Cell
D software suite (Olympus, Soft Imaging Solutions, SiS, GmbH,
Münster, Germany).
2.7. Light and fluorescence microscopy (live cell imaging)
The impact of ABAs upon the viability of macrophages in live cul-
ture was determined directly in plate wells using an EVOS FL cell
imaging system equipped with an LED light source (Thermo Fisher
Scientific, UK).
The location of ABA particles (red lumogallion fluorescence) was
visualised using the RFP fluorescence channel (filter cube λex & λem:
531–540 nm and 593–640 nm respectively).
Positively stained extracellular and intracellular nuclear material
originating from membrane compromised cells (blue DAPI fluores-
cence) was detected using the DAPI fluorescence channel (filter cube
λex & λem: 357–444 nm and 447–560 nm respectively).
The size (diameter) of native and differentiated THP-1 cells was
obtained using the measurement tools available within Cell D software
suite (Olympus, UK).
2.8. Lactate dehydrogenase (LDH) assay
As a general indicator of cell death, the release of lactate dehy-
drogenase (LDH) by THP-1 macrophages was monitored using a com-
mercially available assay kit (Pierce, Thermo Scientific, UK) according
to the manufacturer's instructions.
Negative assay controls in the absence of cells included R10 medium
only (med) in addition to medium spiked with ABAs (med ABA)
(1.7 μg/mL Al). The latter was included in order to determine whether
ABAs themselves had the potential to interfere directly with the assay
results.
Maximum LDH release values (positive controls) were obtained via
pre-treatment of designated wells with 10 μL lysis buffer (10% v/v per
well) for 45min (37 °C, 5% CO2). The potential for LDH adsorption onto
the surface of ABAs also prompted the introduction of supplementary
ABA-containing positive controls (max ABA) (1.7 μg/mL Al).
Briefly, a small amount of supernatant (50 μL) from treated and
control wells was removed and transferred to a new 96-well plate. An
equivalent volume of LDH reaction solution was added to each sample
and the plate was incubated at RT for 30min in the absence of light to
allow colour development. The amount of LDH within each supernatant
was derived from the enzyme-mediated reduction of INT to formazan
which was measured at Abs 490 nm (680 nm background correction)
using a TECAN M200 infinite pro plate reader. Mean absorbance values
per condition were derived from the values obtained across triplicate
wells provided that RSD<10%. The % LDH released by untreated (un)
and treated cells (t) was calculated in accordance with Eqs. (1) & (2)
respectively: ×(([A] –[A] )/([A] –[A] )) 100un med max med (1)×(([A] –[A] )/([A] –[A] )) 100t med ABA max ABA med ABA (2)
2.9. Statistical analyses
Statistical significance was determined using GraphPad Prism v.7
software and dataset normality was determined using a Shapiro-Wilk
test before subsequent comparisons were conducted. Differences in size
distribution parameters were analysed using a Friedman test followed
by Dunn-post hoc tests. Time-dependent multiple comparisons were
performed using a one or two-way ANOVA with repeated measures
followed by Tukey or Sidak's post-hoc tests respectively. Multiple in-
dependent comparisons were performed using an ordinary one-way
ANOVA followed by Tukey post hoc tests. Statistical significance was
confirmed when a comparison yielded a P value of ≤0.05.
3. Results
3.1. Validation of differentiation protocol
In lieu of traditional immunocytochemical staining for markers of
THP-1 differentiation including CD14 and CD11b, the success of the
PMA-mediated differentiation procedure was determined through vi-
sual assessment of morphological changes to cells.
Native THP-1 monocytes (Fig. 1A) presented as a homogenous po-
pulation of predominantly spherical entities ranging from 10.2–20.3 μm
in size (d50–12.1 μm, Fig. 1D), which on occasion exhibited evidence of
sparsely distributed granules within their cytoplasmic space. Following
PMA withdrawal, cells became generally more heterogenous with re-
spect to cytoplasmic volume, morphology and granularity (Fig. 1B & C).
The former was characterised by a significant elevation in the overall
breadth of the size distribution obtained and increase in the median size
of cells (8.4–65.2 μm and 21.0 μm respectively, P=0.0002), trends
which remained consistent on the second day of analysis
(11.7–100.7 μm and 20.9 μm respectively, P=0.59). Extensive cellular
elongation, adherence and generation of pseudopodia were also fre-
quently observed along with heightened incidence of granule formation
within the intracellular environment.
3.2. Survival of THP-1 macrophages post PMA withdrawal
In order to determine the maximum duration over which cells re-
mained viable in vitro and thus could be monitored in the presence of
ABAs, the membrane integrity of THP-1 macrophages was determined
over a period of 9 days post PMA withdrawal.
Bereft of medium replenishment, the percentage of macrophagic
LDH discharged into the extracellular environment was consistently
low over the first 3 days, accounting for between 6.9 ± 4.9 and
9.0 ± 3.3% of the maximum sample recovery (P=1) (Fig. 2 – purple
series). The amount of LDH released by cells increased to 29.1 ± 5.6%
after 5 days; however, this increase in value was not statistically sig-
nificant with respect to that obtained for the previous time point
(P=0.14). By the end of the experiment (day 8), enzymatic release had
burgeoned substantially to 53.8 ± 10.6% indicating that below half
the population of macrophages in culture remained viable under these
conditions.
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Taking these results into consideration, similar experiments were
performed with the inclusion of a medium replacement every three days,
in order to assess whether this latter heightened cell death was due to
nutrient depletion and thus could be ameliorated (Fig. 2 – blue series).
Following the first medium change, the amount of LDH released by day 5
had decreased relative to that measured in the absence of nutrient re-
plenishment (19.8 ± 2.3 vs. 29.1 ± 5.6%, P=0.006) and appeared to
plateau at moderate levels thereafter (Day 9 - 18.2 ± 2.1%).
3.3. Macrophagic loading of ABA particles following short term exposure
To optimise the adjuvant exposure protocol and maximise the
amount of intracellular particulate loading prior to viability
measurements, the interaction of Alhydrogel® (Alh) (1.7 μg/mL Al)
with differentiated macrophages was monitored using lumogallion over
the course of two days (Fig. 3).
The cytosol of control macrophages stained with lumogallion in the
absence of ABAs emitted an extremely weak, orange autofluorescence
signal and DAPI positive fluorescence (blue) confirmed the presence of
multiple intact and regular nuclei (Fig. 3A). Following initial 3 h
treatment with Alh (Fig. 3B), intense punctate orange fluorescence was
detected both in the extracellular environment and intracellular com-
partment of cells as well as surrounding their membrane boundary.
Particulate internalisation appeared to increase with contact time re-
sulting in an extensive depletion of adjuvant from the culture medium
24 h post exposure and beyond (Fig. 3C & D). As a consequence,
heightened cytoplasmic loading was frequently observed, although this
was slightly more pronounced in samples treated for 24 h.
3.4. Survival of THP-1 macrophages treated with ABAs – day 1
In light of the results obtained for macrophage survival and ABA
uptake, the survival of macrophages in the presence of ABAs (1.7 μg/mL
Al) was analysed over a period of 7 days following treatment, which
occurred on day 2 post PMA withdrawal.
After 24 h exposure to ABA particles, intense red lumogallion
fluorescence was typically observed both within membrane boundaries
and the surrounding peripheries of macrophages treated with Alh and
Adju-Phos® (Adj) (Fig. 4B & C, respectively) in comparison to control
cells, which demonstrated no appreciable lumogallion signal (Fig. 4A).
Cellular loading appeared heterogenous in nature, varying between
cytosolic saturation and limited incidence of intracellular particulates.
However, the majority of cells sampled appear to exhibit some degree
of intracellular or peripheral lumogallion fluorescence with limited
differences in the former visualised between Adj treatments vs. those
spiked with Alh (91.8 ± 5.8 vs. 90.5 ± 1.8%) (Table 1). Furthermore,
only a few of these cells demonstrated DAPI positive nuclear staining
indicating that a high percentage remained viable under these condi-
tions (9.9 ± 6.5 & 5.5 ± 0.5% respectively).
The amount of LDH released by Alh-treated macrophages also re-
mained low and did not deviate significantly from that observed in their
untreated counterparts (11.1 ± 1.7 vs. 7.2 ± 2.7%, P=0.67) (Fig. 4D).
Fig. 1. Morphological characteristics of
THP-1 monocytes exposed to 50 nM
PMA for 15min (A) and post with-
drawal (24 and 48 h – panel B & C re-
spectively). Images were taken on
brightfield channel at a magnification
of 400× and scale bars represent
100 μm. Panel D shows the size dis-
tribution of cells obtained at each time
point as derived from n=30 in-
dividual measurements. Blue dotted
lines represent the span of the dis-
tribution whereas the interquartile
range and d50 values are highlighted
by purple boxes and blue lines respec-
tively.
Fig. 2. Viability of THP-1 macrophages over a maximum of 9 days post dif-
ferentiation (50 nM PMA for 48 h). Data shows the % LDH release of untreated
macrophages relative to that obtained for respective positive controls (max.
LDH release). The purple data series represents values obtained for cells where
no medium change was conducted while those highlighted in blue were subject
to medium replenishment every three days. Error bars represent± SD of the
measurement where n=3. (For interpretation of the references to colour in this
figure legend, the reader is referred to the web version of this article.)
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Nevertheless, Adj did facilitate a significant elevation in total enzymatic
discharge vs. the control (16.0 ± 1.0 vs. 7.2 ± 2.7%, P=0.03), although
no difference in release was observed between adjuvant groups (P=0.07).
3.5. Survival of THP-1 macrophages treated with ABAs – Day 3
ABA particles continued to persist within the intracellular com-
partment of THP-1 macrophages 3 days following treatment (Figs. 5B &
C). Patterns of loading and the number of aluminium positive cells were
similar to that observed on day 1 with the latter accounting for
93.8 ± 3.6 & 88.5 ± 8.8% of the population surveyed (Alh and Adj
respectively). Of these cells only 8.6 ± 4.4 & 10.1 ± 5.9% exhibited
nuclei labelled by DAPI staining.
LDH levels in the extracellular environment of untreated cells in-
creased relative to those detected on day 1 of the experiment
(19.8 ± 2.3 vs.7.2 ± 2.7%, P=0.0008) as did those observed in both
adjuvant treatments (Alh and Adj – 26.7 ± 0.4 & 28.5 ± 5.2%,
P=0.0003 & 0.002 respectively) (Fig. 7). The presence of ABA parti-
cles, however, did not appear to accelerate LDH release in comparison
to untreated cells (P=0.31 & 0.23 respectively) nor did the species of
adjuvant administered (P=0.96) (Fig. 5D).
3.6. Survival of THP-1 macrophages treated with ABAs – day 7
By day 7, a substantial proportion of cells appeared to have reverted
to a rounded morphology reminiscent of native THP-1 cells (de-
Fig. 3. Brightfield, lumogallion (NIB)
and DAPI (WU) overlay images of THP-
1 macrophages exposed to Alh (1.7 μg/
mL Al). Panel A shows untreated cells
24 h post PMA withdrawal while panels
B, C & D represent cells in the presence
of adjuvant 3, 24 & 48 h post treatment
respectively. Images were taken at a
final magnification of 400× and scale
bars represent 50 μm. Cells pictured in
magnified inserts are identified by an
asterisk and arrows highlight inter-
nalised aluminium particles.
Fig. 4. Brightfield, phase contrast, lu-
mogallion (RFP) and DAPI (WU)
overlay images of THP-1 macrophages
exposed to ABA particles (1.7 μg/mL
Al) for 24 h. Panel A shows untreated
cells 3 days post PMA withdrawal while
panels B & C represent cells in the
presence of Alh and Adj on day 1 post
treatment respectively. Images were
taken at a final magnification of 400×
and scale bars represent 100 μm. Cells
pictured in magnified inserts are iden-
tified by an asterisk and arrows high-
light internalised aluminium particles.
Panel D shows the LDH release (%)
induced by each condition relative to
that obtained for respective positive
controls (max. LDH release). Error bars
represent± SD of the measurement
where n=3.
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differentiation); however, a few macrophage-like entities did persist
and cellular adherence remained satisfactory (Fig. 6A). While loading
remained intensive within a small proportion of cells (Fig. 6B & C), the
number of cells expressing a positive signal for Al decreased to
57.1 ± 11.7 and 61.4 ± 5.5% (Alh and Adj, respectively). The
number of labelled nuclei witnessed within such populations accounted
for 8.1 ± 7.1 and 3.2 ± 2.0%, the latter being substantially smaller
than that observed on day 3.
LDH release appeared to plateau under all conditions in relation to
that measured on the previous time point (Control, Alh & Adj -
18.2 ± 2.1, 26.9 ± 4.9 & 30.5 ± 1.3%, P=0.13, 0.75 & 0.06 re-
spectively). Variations between ABA treated and untreated groups were
also inconsequential at this stage (Alh & Adj vs. control - P=0.51 &
0.15 respectively) as were those observed amongst different adjuvant
treatments (P=0.60) (Fig. 6D).
4. Discussion
Our data have revealed, for the first time, that THP-1 macrophages
can survive for extended periods in vitro despite significant in-
tracellular burdens of ABAs. Given that the amount of Al encountered at
the injection site can be substantial (up to 0.85mg/dose if the Al
concentration of the vaccine is determined by assay [46]), we are aware
that our use of such low doses of ABAs, in this case 1.7 μg/mL, may be
considered a potential caveat of this research. However, this study was
not intended to mimic the in vivo concentration of Al administered at
the injection site but rather to establish if: i) ABAs could be inter-
nalised/recognised by THP-1 macrophages and ii) to determine if the
presence of cytosolic Al was directly responsible for cell death and thus
impacted the long-term survival of these cells. At higher concentrations
of Al (12.5 μg/mL) cells were often masked by the swathe of inorganic
material, which impeded the direct visualisation of such events (data
not shown). Therefore, in order to definitively achieve our aims, an
optimised and very low dose of Al had to be applied.
In an attempt to elucidate the impact of ABAs upon the survival of
macrophages in vitro, the studies performed in this work employed the
use of cells differentiated from a malignant monocytic precursor (THP-
1), which possess a similar phenotype to primary cells from a similar
lineage [47–51]. The phagocytic capacity of these cells for inorganic
particles is also similar to that of monocyte-derived macrophages
(MDMs) provided that both the rest period and contact time with the
differentiating agent are sufficient [47,52]. Initial experiments in-
dicated that exposure to increasing concentrations of PMA (100 nM
max.) did not adversely impact the longevity of THP-1 macrophages
relative to the application of lower concentrations (Fig. S1). However,
cellular survival was prolonged and overall death reduced through the
application of medium changes every three days. While our study did
not use the lowest recommended concentration of PMA required to
induce stable differentiation of THP-1 cells, levels of adherence fol-
lowing long-term withdrawal (5 days) were reportedly higher in po-
pulations differentiated with higher doses of PMA [50]. This provides a
substantial advantage in terms of being able to monitor such cells over
extended periods and thus a concentration of 50 nM was selected for
use in active experiments. Nevertheless, care must be taken when using
high concentrations of differentiating agents as cellular responses to
pathogenic stimuli, in particular, can deviate substantially from those
of MDMs [51]. Limitations of this model also include the tendency of
differentiated cells to revert to a monocytic phenotype approximately
one week following PMA removal (Fig. 6A), which may lead to an al-
teration in their response to ABAs at latter experimental junctures.
Given the propensity of native THP-1 cells to proliferate in vitro, it is
Table 1
Percentage of cells exhibiting evidence of Al internalisation or association and
the percentage of Al positive cells which appeared to be dead (DAPI positive
nuclei). Data for each condition was derived from counts obtained from three
independent representative images taken at 200× magnification (see Figs.





Al positive dead/dying cells
(% ± SD)
Alh
1 90.5 ± 1.8 5.5 ± 0.5
3 93.8 ± 3.6 8.6 ± 4.4
7 57.1 ± 11.7 8.1 ± 7.1
Adj
1 91.8 ± 5.8 9.9 ± 6.5
3 88.5 ± 8.8 10.1 ± 5.9
7 61.4 ± 5.5 3.2 ± 2.0
Fig. 5. Brightfield, phase contrast, lu-
mogallion (RFP) and DAPI (WU)
overlay images of THP-1 macrophages
exposed to ABA particles (1.7 μg/mL
Al) for 3 days. Panel A shows untreated
cells 5 days post PMA withdrawal while
panels B & C represent cells in the
presence of Alh and Adj on day 3 post
treatment respectively. Images were
taken at a final magnification of 400×
and scale bars represent 100 μm. Cells
pictured in magnified inserts are iden-
tified by an asterisk. Panel D shows the
LDH release (%) induced by each con-
dition relative to that obtained for re-
spective positive controls (max. LDH
release). Error bars represent± SD of
the measurement where n=3.
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this particular transition that may account for the decrease in Al and
DAPI positive cells observed on day 7 of the experiment vs. that of the
preceding time point. However, while it must be emphasised that there
are differences between primary MDMs and those derived from cell
lines [47,51,52], THP-1 macrophages provide both a stable and ap-
propriate model to monitor the impact of ABA phagocytosis in vitro.
Neither form of ABA caused specific interference with the results
generated by the LDH assay at the concentrations used herein (data not
shown). In fact, this method has been used to successfully evaluate the
viability of cells exposed to higher concentrations of AH (1mg/mL Al)
without significant artefacts being explicitly encountered [53]. Our
decision to modify the assay through the use of ABA-spiked maximum
LDH controls was predicated upon the notion that micro-particulates
can inactivate and adsorb enzymes released by dying cells, leading to
the generation of false negative readings [54]. Other limitations of this
assay include the inherent LDH activity of serum containing culture
medium [55]; however, this was accounted for using medium only
controls as absorbance values were not exceptionally high. The com-
plementary measurement of metabolic activity, despite its popularity in
this context, was not attempted owing to the documented influence of
ABAs on mitochondrial function [56]. LDH data was instead paired
with direct dead cell labelling (DAPI staining) in order to evaluate the
impact of ABAs upon individual cells as well as the total population. In
conjunction, these methods allowed the relationship between particle
recognition, uptake and viability to be reliably elucidated.
Aluminium particulates were observed both within the cytoplasmic
space and at the cellular margin of macrophages at junctures as early as
3 h post exposure, which is consistent with the size distribution pre-
viously determined for these species in R10 medium (ca 1 μm) [21].
Particulate loading was extensive & heterogenous in nature and the
degree of cytosolic burden typically observed in individual cells was
moderate to high 24–72 h following treatment. The latter was more
pronounced in cells exhibiting rounded morphologies, a phenomenon
perhaps attributed to their lower relative cytoplasmic volume. Previous
communications have inferred that AH is more avidly engulfed by
immature phagocytes [21]; however, qualitative assessment of ABA
uptake herein revealed no observable differences in cellular loading
between adjuvant species at any point during experiments. Further-
more, our results confirm that macrophages both interact with and
internalise ABAs in situ, which is consistent with trends observed by
others in vivo [14,34,35,38–41].
The heightened and prevalent incidence of ABAs within THP-1
macrophages did not necessarily correlate with a concomitant increase
in cell death either on an individual (DAPI staining) or widespread basis
(LDH assay). Early indications did suggest that AP caused a small but
significant reduction in total cell viability relative to untreated controls;
however, this was only apparent on day 1 of the experiment. While the
sensitivity of their progenitors to small amounts of AP has already been
demonstrated [21], macrophages appear more resilient in this context,
conceivably due to their prominent role in pathogenic clearance and
host defence [57]. Our results are also consistent with those
Fig. 6. Brightfield, phase contrast, lu-
mogallion (RFP) and DAPI (WU)
overlay images of THP-1 macrophages
exposed to ABA particles (1.7 μg/mL
Al) for 1 week. Panel A shows un-
treated cells 9 days post PMA with-
drawal while panels B & C represent
cells in the presence of Alh and Adj on
day 7 post treatment respectively.
Images were taken at a final magnifi-
cation of 400× and scale bars re-
present 100 μm. Cells pictured in mag-
nified inserts are identified by an
asterisk and arrows highlight inter-
nalised aluminium particles. Panel D
shows the LDH release (%) induced by
each condition relative to that obtained
for respective positive controls (max.
LDH release). Error bars
represent± SD of the measurement
where n=3.
Fig. 7. LDH release (%) induced in untreated and adjuvant-treated samples
relative to that obtained for respective positive controls (max. LDH release)
over a period of seven days post exposure (control, Alh and Adj – purple, blue
and green series respectively). Error bars represent± SD of the measurement
where n=3. (For interpretation of the references to colour in this figure le-
gend, the reader is referred to the web version of this article.)
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demonstrating that low doses of ABAs increased the life-span of murine
macrophages in the absence of additional stimulating factors, enhan-
cing DNA synthesis through undisclosed pathways [42]. However,
higher concentrations of Al (1mg/mL) administered in the form of AH
prompted a significant elevation in the expiration of peritoneal mac-
rophages in vitro (ca 50%) only 48 h after initial exposure, although
this did not seem to be directly related to particle entrapment [53]. In
combination, these findings indicate that ABAs may exert their influ-
ence upon immune cells in a concentration-dependent biphasic manner
i.e. stimulatory at low and inhibitory at high concentrations. They also
imply that an excess of ABAs in the extracellular milieu may contribute
to the cell death observed when high concentrations are introduced;
however, this hypothesis has yet to be experimentally confirmed.
The relatively low incidence of cellular death directly observed in
populations heavily laden with particles also demonstrates that a large
proportion of THP-1 macrophages are extremely tolerant to large cy-
tosolic burdens of ABAs. It is thus apparent that ABA-mediated cyto-
toxicity may be somewhat independent of particle uptake or that the
majority of cells have diminished susceptibility to particulate induced
toxicity. Crystalline ABAs, in particular, demonstrate membranolytic
activity including the ability to disrupt lysosomes [58–61], a precursor
to immune cell necrosis and potent stimulus for the induction of hu-
moral responses [61]. Events of this nature, however, appear to be
relatively scarce within host muscle tissue post immunisation and re-
stricted to ca 2.5% of the local population in the short term [62]. In-
deed, the uncontrolled and widespread death of APCs upon contact
with ABAs in vivo appears counterintuitive with regards to the trans-
ference of antigen-adjuvant complexes to the draining lymph nodes, a
process reportedly essential for vaccine priming and the generation of
robust immunological responses [20].
In conclusion, this study is the first direct demonstration that the
cellular internalisation of ABAs by macrophages does not necessarily
induce significant levels of cytotoxicity. As a result, the majority of
macrophages remained viable for up to 7 days post treatment. While
such trends also need to be confirmed using primary MDMs, the long-
evity of these cells in vitro indirectly supports their role in cell-medi-
ated particulate trafficking to the draining lymph nodes, which re-
portedly initially peaks around 4–7 days after vaccination [38,40].
Clarification of the precise mechanisms through which ABAs perpetuate
the survival of immunocompetent cells is required in order to better
understand the risks associated with their biological administration in
predisposed individuals, including the slow CCL2-dependent dis-
semination of particles to the brain [38,40,41].
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